– USA, MN – Cardiovascular Systems, Inc. (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of Dr. Sachin Jain, MD, MBA. to its Board as an Independent Director, bringing the Board to nine directors, of whom eight are independent.
“We are pleased to welcome Dr. Sachin Jain as a new independent director to the CSI board,” said Chairman and CEO, Scott Ward. “Sachin’s innovation and leadership in clinical practice, health policy, healthcare delivery and digital health will expand our Board’s understanding of key opportunities to prevent amputations and address disparities in healthcare.”
About Dr. Sachin Jain
Dr. Jain is currently President and CEO of SCAN Group and Health Plan, a mission-driven organization dedicated to the health and wellness of older adults. Before this role, he was President and CEO of CareMore and Aspire Health.
Before CareMore, Dr. Jain was Chief Medical Information & Innovation Officer at Merck & Co. Before this role, Dr. Jain worked in leadership roles at the U.S. Department of Health and Human Services.
Dr. Jain is an adjunct professor of medicine at the Stanford University School of Medicine. Also, Dr. Jain is a respected thought leader in health care delivery and has been recognized as a “Top 50 Most Influential Clinical Leader” and “100 Most Influential People in US Healthcare” by Modern Healthcare. He currently serves as a member of the board of directors for America’s Health Insurance Plans, Abode Hospice, and the Make-A-Wish Foundation. He also serves as an Aspen Institute Health Innovator’s Fellow.
Dr. Jain graduated from Harvard College with a BA in government and continued to earn his MD from Harvard Medical School and MBA from Harvard Business School.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary diseases. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with an existing surgical, catheter, and pharmacological treatment alternatives.
For more information: https://csi360.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.